South Delhi Pharma, New Delhi, India
COTELLIC (cobimetinib) tablets. FDA-Approved. To treat melanoma
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email firstname.lastname@example.org to discuss.
COTELLIC (cobimetinib) tablets is a prescription medicine. COTELLIC (cobimetinib) tablets is used to treat adults with unresectable or metastatic melanoma.
INDICATIONS AND USAGE
COTELLIC is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib
DOSAGE FORMS & STRENGTHS Tablets: 20 mg
Manufactured By: Genentech
Prescribing Information URL: Click Here
South Delhi Pharma facilitate the supply of “COTELLIC (cobimetinib) tablets FDA Approved” medication. Supplied under Named Patient Program to all locations in India and other part of countries. Anti-Cancer drugs is available upon request after fulfilling the legal requirement (if applicable). To get best price share your mobile number and email ID.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
Cobimetinib, sold under the brand name Cotellic, is a MEK inhibitor developed by Exelixis and Genentech (Roche). It is used in combination with vemurafenib, a BRAF inhibitor, to treat melanoma. In November 2015, the U.S. Food and Drug Administration approved cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib (Zelboraf). Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma.
Cobimetinib was awarded orphan drug status by the FDA for malignant melanoma with BRAFV600 mutation in 2014.